These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 34283647

  • 1. Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.
    Benhmida S, Beneux A, Udrescu C, Rouviere O, Horn S, Enachescu C, Lapierre A, Chapet O.
    Br J Radiol; 2021 Nov 01; 94(1127):20210142. PubMed ID: 34283647
    [Abstract] [Full Text] [Related]

  • 2. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
    Ruggieri R, Naccarato S, Stavrev P, Stavreva N, Fersino S, Giaj Levra N, Mazzola R, Mancosu P, Scorsetti M, Alongi F.
    Br J Radiol; 2015 Oct 01; 88(1054):20140736. PubMed ID: 26235142
    [Abstract] [Full Text] [Related]

  • 3. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
    Dubouloz A, Rouzaud M, Tsvang L, Verbakel W, Björkqvist M, Linthout N, Lencart J, Pérez-Moreno JM, Ozen Z, Escude L, Zilli T, Miralbell R.
    Radiat Oncol; 2018 Jun 19; 13(1):114. PubMed ID: 29921291
    [Abstract] [Full Text] [Related]

  • 4. Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function.
    Hwang ME, Mayeda M, Shaish H, Elliston CD, Spina CS, Wenske S, Deutsch I.
    Br J Radiol; 2021 Mar 01; 94(1119):20200433. PubMed ID: 33586999
    [Abstract] [Full Text] [Related]

  • 5. Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial.
    Jaccard M, Zilli T, Dubouloz A, Escude L, Jorcano S, Linthout N, Bral S, Verbakel W, Bruynzeel A, Björkqvist M, Minn H, Tsvang L, Symon Z, Lencart J, Oliveira A, Ozen Z, Abacioglu U, Pérez-Moreno JM, Rubio C, Rouzaud M, Miralbell R.
    Int J Radiat Oncol Biol Phys; 2020 Nov 15; 108(4):1047-1054. PubMed ID: 32535161
    [Abstract] [Full Text] [Related]

  • 6. Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy.
    Chapet O, Udrescu C, Tanguy R, Ruffion A, Fenoglietto P, Sotton MP, Devonec M, Colombel M, Jalade P, Azria D.
    Int J Radiat Oncol Biol Phys; 2014 Feb 01; 88(2):425-32. PubMed ID: 24411613
    [Abstract] [Full Text] [Related]

  • 7. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
    Ciabatti S, Ntreta M, Buwenge M, Gaudiano C, Sessagesimi E, Romani F, Angelini AL, Cammelli S, Macchia G, Deodato F, Zamagni A, Golfieri R, Morganti AG, Cilla S.
    Med Dosim; 2014 Feb 01; 44(4):356-364. PubMed ID: 30955990
    [Abstract] [Full Text] [Related]

  • 8. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D, Sood S, Badkul R, Jiang H, McClinton C, Lominska C, Kumar P, Wang F.
    J Appl Clin Med Phys; 2016 May 08; 17(3):277-293. PubMed ID: 27167284
    [Abstract] [Full Text] [Related]

  • 9. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
    Outaggarts Z, Wegener D, Berger B, Zips D, Paulsen F, Bleif M, Thorwarth D, Alber M, Dohm O, Müller AC.
    Acta Oncol; 2020 Aug 08; 59(8):911-917. PubMed ID: 32436467
    [Abstract] [Full Text] [Related]

  • 10. Potential interest of developing an integrated boost dose escalation for stereotactic irradiation of primary prostate cancer.
    Udrescu C, Rouvière O, Enachescu C, Sotton MP, Bouffard-Vercelli J, Jalade P, Chapet O.
    Phys Med; 2014 May 08; 30(3):320-5. PubMed ID: 24169295
    [Abstract] [Full Text] [Related]

  • 11. Neurovascular bundle-sparing radiotherapy for prostate cancer using MRI-CT registration: A dosimetric feasibility study.
    Cassidy RJ, Yang X, Liu T, Thomas M, Nour SG, Jani AB.
    Med Dosim; 2014 May 08; 41(4):339-343. PubMed ID: 27745996
    [Abstract] [Full Text] [Related]

  • 12. Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT.
    Wang L, Movsas B, Jacob R, Fourkal E, Chen L, Price R, Feigenberg S, Konski A, Pollack A, Ma C.
    J Appl Clin Med Phys; 2004 May 08; 5(2):29-41. PubMed ID: 15738911
    [Abstract] [Full Text] [Related]

  • 13. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
    Kishan AU, Park SJ, King CR, Roberts K, Kupelian PA, Steinberg ML, Kamrava M.
    Br J Radiol; 2015 May 08; 88(1056):20150658. PubMed ID: 26463234
    [Abstract] [Full Text] [Related]

  • 14. Dosimetric and radiobiological consequences of computed tomography-guided adaptive strategies for intensity modulated radiation therapy of the prostate.
    Battista JJ, Johnson C, Turnbull D, Kempe J, Bzdusek K, Van Dyk J, Bauman G.
    Int J Radiat Oncol Biol Phys; 2013 Dec 01; 87(5):874-80. PubMed ID: 23978708
    [Abstract] [Full Text] [Related]

  • 15. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
    Pham J, Neilsen BK, Liu H, Cao M, Yang Y, Sheng K, Ma TM, Kishan AU, Ruan D.
    Med Phys; 2024 Jan 01; 51(1):612-621. PubMed ID: 38055353
    [Abstract] [Full Text] [Related]

  • 16. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
    Fukuda S, Seo Y, Shiomi H, Yamada Y, Ogata T, Morimoto M, Konishi K, Yoshioka Y, Ogawa K.
    J Radiat Res; 2014 Nov 01; 55(6):1114-21. PubMed ID: 24957754
    [Abstract] [Full Text] [Related]

  • 17. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Raben A, Chen H, Grebler A, Geltzeiler J, Geltzeiler M, Keselman I, Litvin S, Sim S, Hanlon A, Yang J.
    Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1631-8. PubMed ID: 15590195
    [Abstract] [Full Text] [Related]

  • 18. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
    Zapatero A, Castro P, Roch M, Carnero PR, Carroceda S, Rosciupchin AES, Hernández SH, Cogorno L, Iturriaga AG, García DB.
    Radiat Oncol; 2024 May 03; 19(1):54. PubMed ID: 38702761
    [Abstract] [Full Text] [Related]

  • 19. Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability.
    Goddard LC, Brodin NP, Bodner WR, Garg MK, Tomé WA.
    Br J Radiol; 2018 May 03; 91(1085):20180010. PubMed ID: 29436852
    [Abstract] [Full Text] [Related]

  • 20. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    van Lin EN, Fütterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, Huisman HJ, Scheenen TW, Witjes JA, Leer JW, Barentsz JO, Visser AG.
    Int J Radiat Oncol Biol Phys; 2006 May 01; 65(1):291-303. PubMed ID: 16618584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.